PEXEVA®

Noven Therapeutics respects the privacy of visitors to its online sites, and as a result, we will abide by this Internet Privacy Statement. This Internet Privacy Statement applies only to those sites that link directly to this Statement when you click on "Privacy Statement" in the website's footer. It does not apply to Noven Therapeutics' activities other than its online sites described above. Through this website, Noven Therapeutics will only collect your personally identifiable information, such as your name, address, telephone number, or e-mail address, and only if you provide it to us. Noven Therapeutics and/or the companies we hire will use this information to comply with your request for information or as otherwise disclosed to you on the web page when you submit your information to us. Anyone wishing to stop receiving communications may do so at any time (unsubscribe or "opt-out") and their personal information will be deleted from our database. From time to time, we may refer to this information to better understand your needs and how we can improve our products and services. We may use this information to contact you. We will not sell or otherwise transfer the personally identifiable information you provide to us at this website to any third parties for their own use unless we tell you when you submit your information to us that we intend to do so.

This website may use a technology called a "cookie". A cookie is a bit of information that our web server sends to your browser file when you have accessed a website. Our cookies help provide additional functionality to the site and aid us in compiling information concerning usage more accurately. For instance, our site may set a cookie on your browser that keeps you from needing to remember and then enter a password more than once during a visit to the site.

Since we are very interested in the successful dissemination of information through this website, we will study visitor trends. Our server will create log files of such information as the IP address from your network, what pages were explored, and the length of the visit. Analysis software will be used to generate reports which will help us learn more about how we can enhance your experience with our website. This information will not be used to try to ascertain who you are or what you are looking at. The log files are purged periodically to save space on the server.

This website uses Internet Protocol (IP) Addresses. An IP Address is a number designated for your computer by your Internet service provider to provide access to the Internet. Generally, an IP address will change every time your computer connects to the Internet. However, if you have a broadband connection, it is a possibility that your IP Address that we may gather, or even perhaps a cookie we use, may contain information that may be deemed identifiable. This could occur due to the fact that by using certain broadband connections, your IP Address would not change (it is "static") and could be associated with your personal computer. We may use your IP Address to gather aggregate information on use.]

This Noven Therapeutics website is not intended or designed to attract children under the age of 13. We do not collect personally identifiable information from any person we know to be under the age of 13.

As a convenience to our visitors, this site currently contains links to a number of websites that we believe may offer useful information. The privacy policy and provisions described here do not apply to those sites. We suggest contacting those sites directly for information on their data collection and distribution policies.

From time to time, Noven Therapeutics may decide to modify its practices and policies, and we reserve the right to revise this Noven Therapeutics Internet Privacy Statement as necessary to disclose such changes in our practices and policies. Any such changes to this Noven Therapeutics Internet Privacy Statement will be promptly communicated on this page. Any information that you submit before the change in policy will be used by Noven Therapeutics and/or the companies we hire in a manner that is consistent with the Noven Therapeutics Internet Privacy Statement in effect at the time you submitted your information.

Continued use of our sites after receiving notice of a change in our privacy statement shall indicate your consent to the use of newly-submitted information in accordance with the changed, amended, or updated Noven Therapeutics Internet Privacy Statement.

Important Safety Information

Suicidality and Antidepressant Drugs
Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of PEXEVA® (paroxetine mesylate) or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. PEXEVA® (paroxetine mesylate) is not approved for use in pediatric patients. (See Warnings: Clinical Worsening and Suicide Risk, Precautions: Information for Patients, and Precautions: Pediatric Use)

All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases.

Concomitant use of PEXEVA® (paroxetine mesylate) in patients taking monoamine oxidase inhibitors (MAOIs), thioridazine, or pimozide is contraindicated. If concomitant use of paroxetine with a 5-hydroxytryptamine receptor agonist (triptan) is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases. PEXEVA® (paroxetine mesylate) tablets are contraindicated in patients with a hypersensitivity to paroxetine or any of the inactive ingredients in PEXEVA® (paroxetine mesylate) tablets.

The most common side effects that have been reported with PEXEVA® include nausea, dry mouth, constipation, decreased appetite, infection, drowsiness, tremor, sweating, muscle weakness, trouble sleeping, abnormal ejaculation, impotence and other male genital disorders, and female genital disorders.

Please see Important Safety Information, including Black Boxed WARNING.

Please see accompanying full Prescribing Information including WARNINGS-Clinical Worsening and Suicide Risk; Usage in Pregnancy: Teratogenic and Nonteratogenic Effects.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.


Copyright © 2010 Noven Therapeutics, LLC All rights reserved. For U.S. Audience Only
Visit Noven Therapeutics